Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
09/2003
09/25/2003US20030181661 Gridlock nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
09/25/2003US20030181659 Thrombopoietin receptor modulating peptide
09/25/2003US20030181658 Exhibit protease activity as a single chain or as an activated two chain form; use of polypeptides to identify compounds that modulate the protease activity thereof and as tumor markers
09/25/2003US20030181587 Thermoplastic resin composition
09/25/2003US20030181531 Preparing a dosage comprising a pharmaceutically effective dosage of a tubulin binding agent; administering the dosage to a subject
09/25/2003US20030181530 Soluble compositions of triphenylethylene antiestrogens
09/25/2003US20030181529 Method for preventing and treating peripheral neuropathy by administering selegiline
09/25/2003US20030181528 Administering to the warm-blooded animal a dose of ketamine sufficient to alleviate symptoms associated with Restless Legs Syndrome
09/25/2003US20030181527 Novel formulations of alpha-2,4-disulfophenyl-n-tert-butylnitrone
09/25/2003US20030181526 Administering formulation comprising urea and dermatologically acceptable excipients for therapy of onychomycosis infection of nail area
09/25/2003US20030181525 Method of treating onychomycosis
09/25/2003US20030181524 Stabilized, non-granulated, immediate release
09/25/2003US20030181521 Use of vegetable butter-based cetyl myristoleate for treating osteoarthritis and other musculoskeletal disease conditions and injuries
09/25/2003US20030181520 Methods of reversing and preventing cardiovascular pathologies
09/25/2003US20030181519 Substituted phenyl naphthalenes as estrogenic agents
09/25/2003US20030181518 Compositions and methods for treating cystic fibrosis
09/25/2003US20030181517 Treatments using venlafaxine
09/25/2003US20030181516 Substance with sedative effect
09/25/2003US20030181515 Administering to a subject in need of pain relief a medicinal ointment comprising an active kavalactone selected from the group consisting of dihydrokawain, dihydromethysticin, kawain and medicinally acceptable carrier
09/25/2003US20030181514 Therapeutic compounds and methods
09/25/2003US20030181512 For therapy and prophylaxis of obesity and hyperlipidemia; side effect reduction
09/25/2003US20030181510 Administering to animal an inhibitor of the protein tyrosine kinase pathway such as genistein or prodrug for inhibiting skeletal muscle regeneration following myectomy
09/25/2003US20030181509 Administering an amino acid precursor of a catecholamine and amino acid precursor of serotonin
09/25/2003US20030181508 For therapy of attention-deficit disorder, depression, obesity, Parkinson's disease, a tic disorder, or an addictive disorder
09/25/2003US20030181507 Use of 3-substituted oxindole derivatives as kcnq potassium channel modulators
09/25/2003US20030181506 Hetercyclic carboxy compounds such as alpha-methyl-2-naphthalene-methyl 2-(4-fluorophenoxy)-5-oxotetrahydrofuran-2-carboxylate used to selectively regulate induction of cytotoxic effecter macrophages
09/25/2003US20030181504 Administering 2-(benzo(g)indazol-1-yl)-ethylamines and 1-(4H-indeno(1,2-c)pyrazol-1-yl)-1-methylethylamines compounds for therapy of glaucoma
09/25/2003US20030181503 Administering 2-(benzo(g)indazol-1-yl)-ethylamines and 1-(4H-indeno(1,2-c)pyrazol-1-yl)-1-methylethylamines compounds for therapy of glaucoma
09/25/2003US20030181502 Methods of treating sepsis
09/25/2003US20030181501 Therapy and prophylaxis of cyclooxygenase-2 mediated conditions and disorders
09/25/2003US20030181500 For therapy and prophylaxis of cardiac failure, the prevention of ischemic coronary heart disease or recurrence of ischemic coronary heart disease
09/25/2003US20030181499 For use as anti-human immunodeficiency virus (HIV) drugs
09/25/2003US20030181498 For therapy of disease mediated by interation of Vascular Cell Adhesion Molecule-1 (VCAM-1) and/or fibronectin and integrin receptor and/or alpha 4 beta 1
09/25/2003US20030181497 Heterocyclic acridone inhibitors of IMPDH enzyme
09/25/2003US20030181495 Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor
09/25/2003US20030181493 Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
09/25/2003US20030181492 Administering amine, mercaptan or acid derivatives of benzene or pyridine for
09/25/2003US20030181491 C2-disubstituted indan-1-ol compounds, their derivatives, processes for their preparation, and their use as pharmaceuticals
09/25/2003US20030181490 For therapy and prophylaxis of acquired immune deficiency syndrome (AIDS), or ARC
09/25/2003US20030181489 For therapy and prophylaxis of cough in warm-blooded animals
09/25/2003US20030181488 Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
09/25/2003US20030181487 Salts of benzimidazole compound and use thereof
09/25/2003US20030181486 Novel use of(r) -(-) -2-[5-(4-fluorophenyl)-3- pyridylmethylaminomethy]-chromane and its physiologically acceptable salts )
09/25/2003US20030181484 New substituted pyridine or piperidine compounds
09/25/2003US20030181481 Therapeutic drugs for treating central nervous system disorders
09/25/2003US20030181480 Methods of modulating serine/threonine protein kinase function with azabenzimidazole-based compounds
09/25/2003US20030181478 A liquid, propellant-free mixtures for treating asthma or chronic obstructive pulmonary disease; tiotropium bromide
09/25/2003US20030181477 Compositions and formulations of 9-nitrocamptothecin polymorphs and methods of use therefor
09/25/2003US20030181476 Compositions and formulations of 9-nitrocamptothecin polymorphs and methods of use thereof
09/25/2003US20030181475 Method of administering buprenorphine to treat depression
09/25/2003US20030181474 2,4-Di(hetero-)arylamino(-oxy)-5-substituted pyrimidines as antineoplastic agents
09/25/2003US20030181473 Farnesyl protein transferase inhibitor combinations with taxane compounds
09/25/2003US20030181472 Inflammation modulators
09/25/2003US20030181471 Substituted (1,3-bis(cyclohexylmethyl)-1,2,3,6-tetrahydro-2,6-dioxo-9h-purin-8-YI)phenyl derivatives, their preparation and their use in the treatment of inflammatory conditions and immune disorders
09/25/2003US20030181470 Heterocyclic compounds and uses thereof as D-alanyl-D-alanine ligase inhibitors
09/25/2003US20030181469 Crystalline and amorphous form of a triazolo(4,5-d)pyrimidine compound
09/25/2003US20030181468 Thiopyrimidine and isothiazolopyrimidine kinase inhibitors
09/25/2003US20030181464 Phenylsulphonylipiperazinyl derivatives as 5-ht receptor ligands
09/25/2003US20030181463 Antiviral azaindole derivatives
09/25/2003US20030181462 Administering synergistic mixtures comprising calcitonin gene related peptide(CGRP) antagonists and serotonin receptor antagonists or ergots, as analgesics or antipyretics
09/25/2003US20030181461 Use of phosphodiesterase antagonists to treat insulin resistance
09/25/2003US20030181460 Tertiary amines formed by reacting chemical intermediates such as 5-(4-fluorophenyl)-3-methyl-1,2,4-thiadiazole and 1-(3-(trifluoromethyl)phenyl)-piperazine, used for prophylaxis of vision defects and as tumor growth modulators
09/25/2003US20030181459 Use of a vitamin combination for the treatment of primary headaches
09/25/2003US20030181458 Preferential serotonin receptors antagonists comprising heterocyclic amines used for prophylaxis or prevention of headaches, sleep, sexual or eating disorders and as antidepressants
09/25/2003US20030181457 Tertiary amides used as preferential inhibitors of cyclic guanosine 3',5'-monophosphate specific phosphodiesterase, for prophylaxis of cardiovascular and sexual disorders
09/25/2003US20030181456 Heterocyclic amines used as antiemetics for prophylaxis of irritable bowel syndrome constipation, diarrhea, dyspepsia, nausea or vomiting
09/25/2003US20030181455 Bicyclic and tricyclic hetroaromatic compounds
09/25/2003US20030181452 Inotropic agents such as (S)-N-tert-butyloxycarbonyl-N-methyl-tyrosyl)-4-(4-nitrophenyl)-piperazine, used for preventing and/or prophylaxis of diseases associated with adenosine 5'-triphosphate
09/25/2003US20030181451 Use of triazinetrione sulfoxides for controlling coccidioses
09/25/2003US20030181450 Use of substituted 1-amino-5-phenylpentane-3-ol and/or 1-amino-6-phenylhexane-3-ol compounds as medicaments
09/25/2003US20030181449 Methods and compositions for the treatment of pain
09/25/2003US20030181447 3-(Diarylmethylene)-8-azabicyclo[3.2.1]octane derivatives
09/25/2003US20030181446 Novel N-acylated heterocycles
09/25/2003US20030181445 Administering compounds such as N-(3-(5-Cyano-1-(4-fluoro-phenyl)-1,3-dihydroisobenzofuran-1-yl)-1 -propyl)glycine ethyl ester, for prophylaxis of psychological disorders
09/25/2003US20030181444 Heterocyclic amines such as 4-(3,4-dichlorophenyl)-2-(2-(4-methylpiperazin-1-yl)-benzylidene) -thiomorpholin-3-one, used as antiserotonine agents
09/25/2003US20030181443 Aminothiolester compounds, pharmaceutical and cosmetic compositions containing same and uses thereof
09/25/2003US20030181441 Tumor necrosis factor-alpha converting enzyme antagonists, such as (2S,3S)-4-(4-(3,5-difluro-benzyloxy)-benzenesulfonyl) -2-methyl-thiomorpholine-3-carboxylic acid hydroxyamide, used as antiarthritic or anticarcinogenic agents
09/25/2003US20030181440 Isonipecotamides for the treatment of integrin-mediated disorders
09/25/2003US20030181439 Use of paullone derivatives for making medicines
09/25/2003US20030181437 By reaction of pyrrolobenzothiazepin-9-one with amine to give the corresponding enamine, which is subsequently transformed into the final compound
09/25/2003US20030181436 Administering iodiscorbate compound containing strontium, iodine, ascorbic acid, and a diamagnetic ion, either zinc, bismuth, or potassium
09/25/2003US20030181435 Systemic lupus erythematosus therapy
09/25/2003US20030181434 AlphaAED and betaAED regulation of nuclear transcription, gene regulation, and/or gene expression
09/25/2003US20030181432 Particularly particles of therapeutically useful or carrier substances of a size suitable for inhalation therapy
09/25/2003US20030181431 Control of selective estrogen receptor modulators
09/25/2003US20030181430 Novel topical oestroprogestational compositions with a systemic effect
09/25/2003US20030181429 Topically applying betulinic acid or a betulinic acid derivative to tumor site
09/25/2003US20030181428 Methods and compositions for inhibition of angiogenesis
09/25/2003US20030181426 Compositions and methods for treating pain using cyclooxygenase-1 inhibitors
09/25/2003US20030181425 Lysergol enhances transport of antibiotics across the intestinal gut and cell membrane for better efficacy on the target site
09/25/2003US20030181422 Cardioprotective phosphonates and malonates
09/25/2003US20030181421 Method of administering bisphosphonates
09/25/2003US20030181420 Modulators of LXR
09/25/2003US20030181419 Glucosamine and method of making glucosamine from microbial biomass
09/25/2003US20030181418 Pharmaceutical composition
09/25/2003US20030181417 Nitroderivatives of polysaccharides
09/25/2003US20030181416 Antimicrobial charged polymers that exhibit resistance to lysosomal degradation during kidney filtration and renal passage, compositions and method of use thereof
09/25/2003US20030181415 Use of these compounds for prevention and inhibition of malignant epithelial lesions associated with papilloma virus, such as cervical cancer
09/25/2003US20030181414 Multiparticulate enteric coated and multiparticulate enteric coated prolonged release formulations containing NADH
09/25/2003US20030181411 Contacting and adsorbing an insoluble enzyme inhibitor with a surface stabilizer
1 ... 5330 5331 5332 5333 5334 5335 5336 5337 5338 5339 5340 5341 5342 5343 5344 5345 5346 5347 5348 5349 5350 ... 7860